Published 30 October 2008, doi:10.1136/bmj.a2315
Cite this as: BMJ 2008;337:a2315

News

GlaxoSmithKline to limit payments it makes to US doctors to $150 000 a year

¹ London

The first 150 words of the full text of this article appear below.

GlaxoSmithKline is to limit the advisory payments and honorariums it offers to doctors in the United States to $150 000 (£96 000; 120 000) a doctor a year. The company has also said that it will publish the amount of money it offers to doctors "without exception," although doctors’ names will not be published.

Andrew Witty, chief executive of the company, told the Financial Times, "It’s appropriate that we have a limit on what we pay. In the past, whatever has happened has happened, but in the future there will be strict adherence to these caps, which will be clearer to everybody" (23 Oct, p 22).

A spokeswoman for the company said that it had no plans to introduce a cap on payments to doctors in Europe because "European doctors tend not to get the same amount of money as US doctors."

Two other drug companies, Eli Lilly and . . . [Full text of this article]

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    StumbleUpon    Technorati    What's this?

Relevant Articles

US psychiatrist is fired from radio programme for not disclosing drug company ties

Janice Hopkins Tanne
BMJ 2008 337: a2934. [Extract] [Full Text]

US psychiatrist steps down after questions about drug company payments

Janice Hopkins Tanne
BMJ 2008 337: a2088. [Extract] [Full Text]

Drug company payments to doctors still hard to access despite disclosure laws

Fred Charatan
BMJ 2007 334: 655. [Extract] [Full Text] [PDF]

Rapid Responses:

Read all Rapid Responses

Through the looking glass

Mark H Wilson
bmj.com, 13 Nov 2008 [Full text]

Public disclosure of physician payment

Atif A. Kukaswadia
bmj.com, 22 Nov 2008 [Full text]

Online poll

Find out more>>